Fairmount Funds Management, Director: Spyre Therapeutics SYRE Sell · Filed 06/23

Trade details

Type: Insider sale
Amount: $399,658,667.11
Shares · price: 4,684,781 sh · $85.31 a share
Held after: 0 sh
Stock: Spyre Therapeutics SYRE
Person: Fairmount Funds ManagementDirector
Trade date: 26/06/23
Filed: 26/06/23
Days to filing: 0 days

Sold 100.0% of holdings

Share of holding sold: 100.0%

Spyre Therapeutics trades, last 26 weeks

What else happened in Spyre Therapeutics around then

Filed or reported within 30 days of the trade day · 05/24~07/23

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31
Fairmount Funds ManagementDirector
Planned saleCogent Biosciences
Planned sale
Cogent Biosciences
COGT
$242.6M
7,000,000 sh
$242.6M
Filed 03/31
Traded 03/31